BarryKeithHermanMDMMM(He/Him)

PubMed

• 5 citations
  Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Resul...
  David V. Sheehan, Maria Gasior, Susan L. McElroy, Jana Radewonuk, Barry K. Herman, James I. Hudson> ;Innovations in Clinical Neuroscience. 2018 Jun 1
• 5 citations
  Use and Value of the 7-Item Binge Eating Disorder Screener in Clinical Practice.
  Barry K. Herman, Linda S. Deal, Judith C. Kando, Dana B. DiBenedetti, Lauren Nelson, Sheri Fehnel, T. Michelle Brown> ;The Primary Care Companion for CNS Disorders. 2017 Jun 29
• 1 citations
  Characterization of Binge-Eating Behavior in Individuals With Binge-Eating Disorder in an Adult Population in the United States.
  Manjiri Pawaskar, Kirk Solo, Jason Valant, Emily Schmitt, Millicent Nwankwo, Barry K. Herman> ;The Primary Care Companion for CNS Disorders. 2016 Oct 27
• 83 citations
  Estimating the Prevalence of Binge Eating Disorder in a Community Sample From the United States: Comparing DSM-IV-TR and DSM-5 Criteria
  Nicole Cossrow, Manjiri Pawaskar, Edward A. Witt, Eileen E. Ming, Timothy W. Victor, Barry K. Herman, Thomas A. Wadden, M. Haim Erder> ;The Journal of Clinical Psychiatry. 2016 Aug 24
• 4 citations
  A Register-Based Case-Control Study of Prescription Medication Utilization in Binge-Eating Disorder.
  Hunna J. Watson, Andreas Jangmo, Melissa A. Munn-Chernoff, Laura M. Thornton, Elisabeth Welch, Camilla Wiklund, Yvonne von Hausswolff-Juhlin, Claes Norring, Barry K. H...> ;The Primary Care Companion for CNS Disorders. 2016 Jul 7
• 41 citations
  Development of the 7-Item Binge-Eating Disorder Screener (BEDS-7).
  Barry K. Herman, Linda S. Deal, Dana B. DiBenedetti, Lauren Nelson, Sheri Fehnel, T. Michelle Brown> ;The Primary Care Companion for CNS Disorders. 2016 Apr 28
• 189 citations
  The neurobiological basis of binge-eating disorder.
  Robert M. Kessler, Peter H. Hutson, Barry K. Herman, Marc N. Potenza> ;Neuroscience and Biobehavioral Reviews. 2016 Apr 1
• 25 citations
  The patient experience with DSM-5-defined binge eating disorder: characteristics, barriers to treatment, and implications for primary care physicians.
  Herman, B. K., Safikhani, S., Hengerer, D., Atkins, N., Kim, A., Cassidy, D., Babcock, T., Agus, S., Lenderking, W. R.> ;Postgraduate medicine. 2014 Oct 9
• 2 citations
  A pilot study of antipsychotic prescribing decisions for acutely-Ill hospitalized patients.
  E. Cabrina Campbell, Melissa DeJesus, Barry K. Herman, Brian Cuffel, Kafi N. Sanders, William Dodge, Vasant Dhopesh, Stanley N. Caroff> ;Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2011 Jan 15
• 27 citations
  The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia
  Stuart Montgomery, Barry K. Herman, Edward Schweizer, F. Mandel> ;International Clinical Psychopharmacology. 2009 Jul 1
• 10 citations
  Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis.
  Dan J. Stein, R. Bruce Lydiard, Barry K. Herman, F. Mandel> ;International Clinical Psychopharmacology. 2009 May 1
• 56 citations
  Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial
  Siegfried Kasper, Barry K. Herman, Giancarlo Nivoli, Michael Van Ameringen, Antonino Petralia, F. Mandel, F. Baldinetti, Borwin Bandelow> ;International Clinical Psychopharmacology. 2009 Mar 1
• 9 citations
  Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.
  William Lawson, Barry K. Herman, Antony Loebel, Irina Lazariciu, Mansoor Malik> ;CNS Spectrums. 2009 Sep 1
• Managing up: dynamic following in an organizational setting.
  Barry K Herman> ;Physician Executive. 2008 Jan 1
• 1 citations
  Point-counterpoint. HIPAA's real effect: the end of medical privacy. A new dilemma for physician executives.
  Barry K Herman, Deborah C Peel> ;Physician Executive. 2004 Jan 1
• Join now to see all

Journal Articles

• Communication between Physicians and Patients with Suspected or Diagnosed Binge Eating Disorder  
  Kornstein, SG, Keck Jr., PE, Herman, BK, Puhl, RM, Wilfley, DE, DiMarco ID, Postgraduate Medicine, 1/1/2015
• The Psychological and Medical Factors Associated With Untreated Binge Eating Disorder  
  Sheehan DV, Herman BK, Prim Care Companion CNS Disord, 1/1/2015
• The Patient Experience with DSM-5-defined Binge Eating Disorder: Characteristics, Barriers to Treatment and Implications for Primary Care Physicians  
  Herman, BK, Safikhani, S, Hengerer, D, Atkins, N, Kim, A, Cassidy, D, Babcock, T, Agus, S, Lenderking, W., Postgraduate Medicine, 1/1/2014
• The Year in Review: The American Association of Psychiatric Administrators  
  Herman, BK, Journal of Psychiatric Administration and Management, 1/1/2013
• Ziprasidone in Black Patients with Schizophrenia: Analysis of Four Short-term, Double Blind Studies  
  Lawson, WB, Herman, BK, Loebel, A, Lazariciu, I, and Malik, M, CNS Spectr, 1/1/2009
• Long-term Safety and Tolerability of Pregabalin Treatment in Three Open-label Extension Studies in Patients with Fibromyalgia  
  Murphy, K, Zeiher, B, Herman, B, Atkinson, G, Pauer, L, Whelan, L, Journal of Pain, 1/1/2009
• Pregabalin Treatment Improves Fatigue, Function and Self-reported Presenteeism in Fi  
  Murphy, K, Pauer, L, Clauw, D, Herman, B, Ikeda, L, Atkinson, G, Zeiher. B, Journal of Pain, 1/1/2009
• Efficacy of Pregabalin and Venlafaxine-XR in Generalized Anxiety Disorder: Results of a Double-blind, Placebo-controlled 8-week Trial  
  Kasper, S, Herman, B, Nivoli, G, Van Ameringen, M, Petralia, A, Mandel, F, Baldinetti, F, and Bandelow, B., Int Clin Psychopharmacol, 1/1/2009
• Managing Up: Dynamic following in an Organizational Setting  
  Herman, BK, Psychiatrist Administrator, 1/1/2007
• Comments on "Presidential Address: Advocacy as Leadership"  
  Clary C, Loebel A, Lombardo I, Alphs L, Binneman B, Vanderburg D, Warrington L, Parsons B, Fogel I, Herman B, Roberts H, Templeton H, Hughes D, Chappell P, Feltner D, ..., Am J Psychiatry, 1/1/2007
• Comments on "Dose Response and Dose Equivalence of Antipsychotics"  
  Walker JK, Herman BK, Loebel A, J Clin Psychopharmacol, 1/1/2005
• Comments on "Dose Response and Dose Equivalence of Antipsychotics"  
  Walker JK, Herman BK, Loebel A, JClinPsych, 1/1/2004
• Treating the Mentally Ill  
  Peele R, Kline L, Herman B, Health Aff (Millwood), 1/1/2001
• Another Way to Regain Control  
  Herman BK, Tex Med, 1/1/1998
• Triazolam Used to Treat Jet Lag: Dose and Direction Effects in a Questionnaire Study  
  Seidel WF, Cohen SA, Bliwise NG, Herman B, Dement WC, Sleep Research, 1/1/1987
• An Overlooked Group: Giving Pharmaceutical Doc-execs Their Due Respect  
  Lazarus, A, Herman B, Modern Physician, 1/9./2006
• Validation of the Yale-brown Obsessive Compulsive Scale Modified for Binge Eating  
  Deal LS, Wirth RJ, Gasior M, Herman BK, McElroy SL., Int J Eat Disord, 1/1./2015
• Special Report: Practice Management  
  Psychiatric Times, 1/7./2010
• Comparative Efficacy of Pregabalin and Benzodiazepines in Treating the Psychic and Somatic Symptoms of Generalized Anxiety Disorder  
  Lydiard RB, Rickels K, Herman B, Feltner DE., Int J Neuropsychopharmacol, 1/9./2009
• Join now to see all

Books/Book Chapters

• Privacy: Opposing Viewpoints Series 
  Chapter: Federal Law Violates Patients' Privacy 
  Page 141.0 - 148.0Herman, Barry K. and Peel, Deborah C.Editors: Carroll, Jamuna.Thompson Gale, MI2006
• Master Clinicians on Treating the Regressed Patient. 
  Chapter: Preface 
  Herman BKEditors: Boyer, L. Bryce & Giovacchini, Peter L..Jason Aronson, Northvale, NJ1993

Abstracts/Posters

• Partnering with the Pharmaceutical Industry
  Herman, BK, Fegert, JM, Baron, D., Turkish Journal of Psychiatry, 1/1/2006
• Ziprasidone vs Haloperidol for the Treatment of Agitation
  Citrome, L, Brook, S, Herman, BK, Loebel, A, Mandel, F, Society for Biological Psychiatry, Atlanta, GA, 1/1/2005
• Ziprasidone vs Haloperidol for the Treatment of Agitation
  Citrome, L, Brook, S, Herman, BK, Loebel, A, Mandel, F, American Psychiatric Association Annual Meeting, Atlanta, GA, 1/1/2005
• Development of the Binge-Eating Disorder Screener
  Herman B, Deal L, DiBenedetti D, Nelson L, Fehnel S, Brown TM., Eating Disorders Research Society (EDRS) Annual Meeting, Taormina, Sicily, 1/17/2015
• Time Course of the Effects of Lisdexamfetamine Dimesylate in Two Phase 3 Randomized, Double-blind, Placebo-controlled Trials in Adults with Binge Eating Disorder
  McElroy, S, Hudson, J, Gasior, M, Herman, B, Radewonuk, J, Wilfley, D, Busner, J, American Society of Clinical Psychopharmacology Annual Meeting, Miami Beach, FL, 1/22/2015
• Effects of Lisdexamfetamine Dimesylate on Functional Impairment on the Sheehan Disability Scale in Adults with Moderate to Severe Binge Eating Disorder: Results from ...
  Sheehan, D, Gasior, M, McElroy, S, Radewonuk, J, Herman, B, Pawaskar, M, Hudson, J., American Society of Clinical Psychopharmacology Annual Meeting, Miami Beach, FL, 1/22/2015
• Development of the Binge-Eating Disorder Screener
  Herman B, Deal L, DiBenedetti D, Nelson L, Fehnel S, Brown TM., American Psychiatric Association (APA) Annual Meeting, Toronto, Canada, 1/16/2015
• Characterization of Binge Eating Behavior in Individuals with Binge Eating Disorder in a US Adult Population
  Pawaskar M, Herman B, Solo K, Valant J, Conway E, Nwankwo M, Grilo C., American Psychiatric Association (APA) Scientific Meeting, Toronto, Canada, 1/16/2015
• Demographic and Clinical Profiles in an Adult Study Population with Moderate to Severe Binge Eating Disorder: A Pooled Analysis of 2 Phase 3, Randomized, Double-Blind,...
  McElroy S, Hudson J, Gasior M, Herman B, Radewonuk J, Grilo G, International Conference on Eating Disorders (ICED) Scientific Meeting, Boston, MA, 1/23/2015
• Communication between Psychiatrisrs and Patients with Suspected or Diagnosed Binge Eating Disorder: Differences in Perspective
  Kornstein S, Keck P, Herman B, Puhl R, Wilfley D, DiMarco I, Charap E., American Psychiatric Association Institute on Psychiatric Services (APA-IPS) Meeting, San Francisco, CA, 1/30/2014
• Validation of Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating to Support Use in Clinical Trials as a Measure of Treatment Benefit
  Deal L, Wirth RJ, Herman B, Gasior M, McElroy S., Eating Disorders Research Society (EDRS) Meeting, San Diego, CA, 1/9./2014
• Validation of the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating to Support Use in Clinical Trials as a Measure of Treatment Benefit
  Deal, L, Wirth, R, Herman, BK, Gasior, M, McElroy, S., American Society of Clinical Psychopharmacology (ASCP) Meeting, Hollywood, FL, 1/17/2014
• Association of Binge Eating Disorder with Productivity and Functioning in a Representative Sample of Adults
  Cossrow, N, Supina, D, Babcock, T, Herman, B, Pawaskar, M, Russo, LJ, The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual Meeting, Montreal, Canada, 1/30/2014
• Binge Eating Disorder Patient Characteristics and Barriers to Treatment: A Qualitative Study
  Herman, BK, Safkhani, S, Hengerer, D, Atkins, N, Kim, A, Cassidy, D, Babcock, T, Lenderking, WR, APA Annual Meeting, New York, NY, 1/6./2014
• Survey of Binge Eating Disorder Recognition, Diagnosis, Treatment and Referral in US Physician Practices
  Supina, D, Herman, BK, Frye, C, Shillington, A, Mitchell, J, APA Annual Meeting, New York, NY, 1/6./2014
• Long-term Safety and Tolerability of Lurasidone in Patients with Schizophrenia: Results of a 6-month, Open -label Extension Study
  Stahl, SM, Cucchiaro, J, Simonelli, D, Severs, J, Herman, B, Loebel, A, NEI Global Psychopharmacology Congress, Colorado Springs, CO, 1/10/2011
• Long-term Safety and Tolerability of Lurasidone in Patients with Schizophrenia: Results of a 6-month, Open -label Extension Study
  Stahl, SM, Cucchiaro, J, Simonelli, D, Severs, J, Herman, B, Loebel, A, APA Institute on Psychiatric Services, San Francisco, CA, 1/27/2011
• Impact of Lurasidone and Olanzapine on Framingham Ten-year Coronary Heart Disease Risk Estimate in Schizophrenia
  Newcomer, J, Pikalov, A, Cucchiaro, J, Siu, C, Herman, B, Loebel, A, APA Institute on Psychiatric Services, San Francisco, CA, 1/27/2011
• Lurasidone in the Treatment of Schizophrenia: Results of the Double-blind, Placebo-controlled PEARL 2 Trial
  Meltzer, H, Silva R, Ogasa, M, Ku, J, Phillips, D, Dimonelli, D, Kalali, A, Herman, BK, Loebel A, US Psychiatric and Mental Health Congress, Orlando, FL, 1/18/2010
• Tension in Generalized Anxiety Disorder: A Relatively Neglected Treatment Target
  Stein, DJ, Mandel, FS, Szczypa, P, Schweizer, E and Herman, BK, American Psychiatric Association Annual Meeting, San Francisco, CA, 1/16/2009
• Is Speed of Onset of Anti-Anxiety Efficacy with Pregabalin Influenced by Starting Dose?
  Herman, BK and Mandel, F, European Psychiatric Association Annual Meeting, Lisbon, Portugal, 1/24/2009
• Comparison of Sleep Outcomes in Generalized Anxiety Disorder Following Treatment with Pregabalin or Venlafaxine-XR
  Herman, BK, Mychaskiw, MA, Mandel, F, European Psychiatric Association Annual Meeting, Lisbon, Portugal, 1/24/2009
• Metabolic Risk and Prescribing Decisions in Antipsychotic Therapy
  Campbell, EC, Herman, BK, Cuffel, BJ, Dodge, W, Dhopesh, V, O'Brien, C, Caroff, SN, American College of Neuropsychopharmacology Annual Meeting, Scottsdale, AZ, 1/8./2008
• Psychic and Somatic Anxiety Symptom Burden and Functional Remission in Generalized Anxiety Disorder
  Mychaskiw, M, Hoffman, D, Dodge, W, Herman, B., European Congress of Neuropsychopharmacology, Barcelona, Spain, 1/30/2008
• Efficacy of Pregabalin and Venlafaxine-XR in Generalized Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled 8-Week Trial
  Herman, B, Nivoli, G, Petralia, A, Mandel, F., XXVI Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Munich, Germany, 1/13/2008
• Join now to see all